---
document_datetime: 2025-12-02 04:50:52
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vimpat.html
document_name: vimpat.html
version: success
processing_time: 0.1700441
conversion_datetime: 2025-12-28 18:17:38.53459
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vimpat

[RSS](/en/individual-human-medicine.xml/66270)

##### Authorised

This medicine is authorised for use in the European Union

lacosamide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vimpat](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-76360)
- [More information on Vimpat](#more-information-on-vimpat-1250)
- [More information on Vimpat](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vimpat is a medicine used on its own or as an add-on to other epilepsy medicines in the treatment of partial-onset seizures (epileptic fits starting in one specific part of the brain) with or without secondary generalisation (where the abnormal electrical activity spreads through the brain) in patients with epilepsy aged 2 years and older.

Vimpat can also be used as add-on to other epilepsy medicines in the treatment of primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 4 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to have a genetic cause).

Vimpat contains the active substance lacosamide.

Expand section

Collapse section

## How is Vimpat used?

Vimpat can only be obtained with a prescription and is available as tablets, as a syrup and as a solution for infusion (drip) into a vein. Vimpat should be taken twice a day; the dosage depends on the patient's weight and age, as well as whether Vimpat is used alone or with other epilepsy medicines.

Vimpat infusion can be used to begin treatment. It can also be used in patients who are temporarily unable to take the medicine by mouth.

For more information about using Vimpat, see the package leaflet or contact your doctor or pharmacist.

## How does Vimpat work?

The active substance in Vimpat, lacosamide, is an epilepsy medicine. Epilepsy is caused by abnormal electrical activity in the brain. The exact way in which lacosamide works is unclear but it seems to reduce the activity of sodium channels (pores on the surface of nerve cells) that allow electrical impulses to be transmitted between nerve cells. This action may prevent abnormal electrical activity in the brain, reducing the chance of an epileptic fit.

## What benefits of Vimpat have been shown in studies?

**Partial-onset seizures**

Vimpat was effective at reducing partial-onset seizures in three main studies involving a total of 1,308 patients aged 16 years and above also taking other epilepsy medicines. Patients were given Vimpat at a dose of 200 mg, 400 mg or 600 mg a day, or placebo (a dummy treatment) in addition to their existing epilepsy medicines. Taking the results of the three studies together, 34% of the patients taking Vimpat 200 mg a day and 40% of those taking 400 mg a day had a reduction in their seizures by at least half after 12 weeks of treatment. This compared with 23% of the patients receiving placebo. The 600-mg dose was as effective as the 400-mg dose but it had more side effects.

A fourth study involving 888 recently diagnosed patients found that Vimpat, used on its own at a dose of 200 to 600 mg a day, was at least as effective as carbamazepine, another epilepsy medicine. The main measure of effectiveness was the proportion of patients who did not have a partial-onset seizure for at least 6 months after reaching a stable dose. This was found to be 90% in those taking Vimpat and 91% in those taking carbamazepine. Around 78% of Vimpat-treated and 83% of carbamazepine-treated patients did not have a seizure for 12 months.

Two additional studies looked at the appropriate duration of the infusion for Vimpat solution and compared its safety with that of placebo infusions in a total of 199 patients. An additional study in 118 patients was carried out to test that starting treatment with doses of 200 mg Vimpat by infusion, followed by regular doses taken by mouth, can be applied safely and that adequate levels in the body are achieved. The company also provided data to support dosing of Vimpat in children from 2 years of age and supportive results from studies of the safety of Vimpat in this population.

**Tonic-clonic seizures**

A further study involving 242 patients aged from 4 years with idiopathic generalised epilepsy compared Vimpat with placebo, both used with other epilepsy medicines. The study showed that Vimpat lowered the risk of having a tonic-clonic seizure: after 24 weeks of treatment, around 31% of patients taking Vimpat were free from seizures compared with around 17% of patients receiving placebo.

## What are the risks associated with Vimpat?

The most common side effects with Vimpat (seen in more than 1 patient in 10) are dizziness, headache, diplopia (double vision) and nausea (feeling sick). Side effects affecting the nervous system such as dizziness may be higher after a high first dose and dizziness was the most common reason for stopping treatment.

Vimpat must not be used in people who have second- or third-degree AV block (a type of heart rhythm disorder). For the full list of side effects and restrictions with Vimpat, see the package leaflet.

## Why is Vimpat authorised in the EU?

The European Medicines Agency decided that Vimpat, used alone or added to other epilepsy medicines, had been shown to be effective in the treatment of partial-onset and tonic-clonic seizures. Taking its side effects into account, the Agency decided that Vimpat's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vimpat?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vimpat have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vimpat are continuously monitored. Side effects reported with Vimpat are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vimpat

Vimpat received a marketing authorisation valid throughout the EU on 29 August 2008.

Vimpat : EPAR - Medicine overview

Reference Number: EMA/129643/2022

English (EN) (124.11 KB - PDF)

**First published:** 17/09/2008

**Last updated:** 25/03/2024

[View](/en/documents/overview/vimpat-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-498)

български (BG) (149.49 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/bg/documents/overview/vimpat-epar-medicine-overview_bg.pdf)

español (ES) (124.89 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/es/documents/overview/vimpat-epar-medicine-overview_es.pdf)

čeština (CS) (147.37 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/cs/documents/overview/vimpat-epar-medicine-overview_cs.pdf)

dansk (DA) (122.52 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/da/documents/overview/vimpat-epar-medicine-overview_da.pdf)

Deutsch (DE) (126.23 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/de/documents/overview/vimpat-epar-medicine-overview_de.pdf)

eesti keel (ET) (111.14 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/et/documents/overview/vimpat-epar-medicine-overview_et.pdf)

ελληνικά (EL) (148.04 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/el/documents/overview/vimpat-epar-medicine-overview_el.pdf)

français (FR) (125.02 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/fr/documents/overview/vimpat-epar-medicine-overview_fr.pdf)

hrvatski (HR) (145.4 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/hr/documents/overview/vimpat-epar-medicine-overview_hr.pdf)

italiano (IT) (122.11 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/it/documents/overview/vimpat-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (161.75 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/lv/documents/overview/vimpat-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (145.29 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/lt/documents/overview/vimpat-epar-medicine-overview_lt.pdf)

magyar (HU) (147 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/hu/documents/overview/vimpat-epar-medicine-overview_hu.pdf)

Malti (MT) (149.47 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/mt/documents/overview/vimpat-epar-medicine-overview_mt.pdf)

Nederlands (NL) (123.56 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/nl/documents/overview/vimpat-epar-medicine-overview_nl.pdf)

polski (PL) (150.42 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/pl/documents/overview/vimpat-epar-medicine-overview_pl.pdf)

português (PT) (125.23 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/pt/documents/overview/vimpat-epar-medicine-overview_pt.pdf)

română (RO) (143.68 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/ro/documents/overview/vimpat-epar-medicine-overview_ro.pdf)

slovenčina (SK) (147.06 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/sk/documents/overview/vimpat-epar-medicine-overview_sk.pdf)

slovenščina (SL) (145.02 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/sl/documents/overview/vimpat-epar-medicine-overview_sl.pdf)

Suomi (FI) (121.08 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/fi/documents/overview/vimpat-epar-medicine-overview_fi.pdf)

svenska (SV) (122.22 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2024

[View](/sv/documents/overview/vimpat-epar-medicine-overview_sv.pdf)

Vimpat : EPAR - Risk Management Plan

English (EN) (2.74 MB - PDF)

**First published:** 05/09/2019

**Last updated:** 07/11/2023

[View](/en/documents/rmp/vimpat-epar-risk-management-plan_en.pdf)

## Product information

Vimpat : EPAR - Product Information

English (EN) (1.19 MB - PDF)

**First published:** 18/08/2009

**Last updated:** 08/05/2025

[View](/en/documents/product-information/vimpat-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-530)

български (BG) (1.31 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/bg/documents/product-information/vimpat-epar-product-information_bg.pdf)

español (ES) (1.13 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/es/documents/product-information/vimpat-epar-product-information_es.pdf)

čeština (CS) (1.21 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/cs/documents/product-information/vimpat-epar-product-information_cs.pdf)

dansk (DA) (959.86 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/da/documents/product-information/vimpat-epar-product-information_da.pdf)

Deutsch (DE) (1.08 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/de/documents/product-information/vimpat-epar-product-information_de.pdf)

eesti keel (ET) (1016.98 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/et/documents/product-information/vimpat-epar-product-information_et.pdf)

ελληνικά (EL) (1.36 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/el/documents/product-information/vimpat-epar-product-information_el.pdf)

français (FR) (1.12 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/fr/documents/product-information/vimpat-epar-product-information_fr.pdf)

hrvatski (HR) (1.19 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/hr/documents/product-information/vimpat-epar-product-information_hr.pdf)

íslenska (IS) (1010.37 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/is/documents/product-information/vimpat-epar-product-information_is.pdf)

italiano (IT) (1.62 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/it/documents/product-information/vimpat-epar-product-information_it.pdf)

latviešu valoda (LV) (1.21 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/lv/documents/product-information/vimpat-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.22 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/lt/documents/product-information/vimpat-epar-product-information_lt.pdf)

magyar (HU) (1.46 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/hu/documents/product-information/vimpat-epar-product-information_hu.pdf)

Malti (MT) (1.27 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/mt/documents/product-information/vimpat-epar-product-information_mt.pdf)

Nederlands (NL) (1.17 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/nl/documents/product-information/vimpat-epar-product-information_nl.pdf)

norsk (NO) (1.05 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/no/documents/product-information/vimpat-epar-product-information_no.pdf)

polski (PL) (1.43 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/pl/documents/product-information/vimpat-epar-product-information_pl.pdf)

português (PT) (1.2 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/pt/documents/product-information/vimpat-epar-product-information_pt.pdf)

română (RO) (1.25 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/ro/documents/product-information/vimpat-epar-product-information_ro.pdf)

slovenčina (SK) (1.19 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/sk/documents/product-information/vimpat-epar-product-information_sk.pdf)

slovenščina (SL) (1.2 MB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/sl/documents/product-information/vimpat-epar-product-information_sl.pdf)

Suomi (FI) (1023.08 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/fi/documents/product-information/vimpat-epar-product-information_fi.pdf)

svenska (SV) (978.57 KB - PDF)

**First published:**

18/08/2009

**Last updated:**

08/05/2025

[View](/sv/documents/product-information/vimpat-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000268614 08/05/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vimpat : EPAR - All Authorised presentations

English (EN) (43.07 KB - PDF)

**First published:** 17/09/2008

**Last updated:** 25/03/2022

[View](/en/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-8)

български (BG) (163.37 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/bg/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_bg.pdf)

español (ES) (78.21 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/es/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_es.pdf)

čeština (CS) (82.18 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/cs/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (42.48 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/da/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (82 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/de/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (45.12 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/et/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (89.37 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/el/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_el.pdf)

français (FR) (82.31 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/fr/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (78.97 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/hr/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (41.99 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/is/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_is.pdf)

italiano (IT) (41.77 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/it/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (87.08 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/lv/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (87.4 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/lt/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (119.4 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/hu/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (83.45 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/mt/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (74.79 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/nl/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (79.03 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/no/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_no.pdf)

polski (PL) (85.29 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/pl/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_pl.pdf)

português (PT) (80.18 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/pt/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_pt.pdf)

română (RO) (113.75 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/ro/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (83.97 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/sk/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (81.36 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/sl/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (43.53 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/fi/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (77.24 KB - PDF)

**First published:**

17/09/2008

**Last updated:**

25/03/2022

[View](/sv/documents/all-authorised-presentations/vimpat-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vimpat Active substance lacosamide International non-proprietary name (INN) or common name lacosamide Therapeutic area (MeSH) Epilepsy Anatomical therapeutic chemical (ATC) code N03AX18

### Pharmacotherapeutic group

Antiepileptics

### Therapeutic indication

Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.

## Authorisation details

EMA product number EMEA/H/C/000863 Marketing authorisation holder

UCB Pharma SA

Allée de la Recherche 60

Opinion adopted 26/06/2008 Marketing authorisation issued 29/08/2008 Revision 56

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vimpat : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (149.72 KB - PDF)

**First published:** 28/03/2025

**Last updated:** 08/05/2025

[View](/en/documents/procedural-steps-after/vimpat-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vimpat : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (285.66 KB - PDF)

**First published:** 18/08/2009

**Last updated:** 28/03/2025

[View](/en/documents/procedural-steps-after/vimpat-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Vimpat-H-C-000863-P46-051 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-2607756

English (EN) (351.44 KB - PDF)

**First published:** 21/11/2025

[View](/en/documents/variation-report/vimpat-h-c-000863-p46-051-epar-assessment-report_en.pdf-0)

Vimpat-PAM-0000245458 : EPAR - Assessment report

Adopted

Reference Number: EMADOC-1700519818-1850061

English (EN) (445.25 KB - PDF)

**First published:** 23/04/2025

[View](/en/documents/variation-report/vimpat-pam-0000245458-epar-assessment-report_en.pdf)

Vimpat-H-C-000863-P46-051 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/334943/2024

English (EN) (380.81 KB - PDF)

**First published:** 24/07/2024

[View](/en/documents/variation-report/vimpat-h-c-000863-p46-051-epar-assessment-report_en.pdf)

Vimpat-H-C-000863-P46-050 : EPAR - Assessment Report

Adopted

Reference Number: EMA/106809/2024

English (EN) (495.92 KB - PDF)

**First published:** 18/03/2024

[View](/en/documents/variation-report/vimpat-h-c-000863-p46-050-epar-assessment-report_en.pdf)

Vimpat-H-C-000863-P46-049 : EPAR - Assessment Report

Adopted

Reference Number: EMA/106826/2024

English (EN) (321.22 KB - PDF)

**First published:** 18/03/2024

[View](/en/documents/variation-report/vimpat-h-c-000863-p46-049-epar-assessment-report_en.pdf)

Vimpat-H-C-000863-P46-048 : EPAR - Assessment Report

Adopted

Reference Number: EMA/575249/2023

English (EN) (523.86 KB - PDF)

**First published:** 09/01/2024

[View](/en/documents/variation-report/vimpat-h-c-000863-p46-048-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-047 : EPAR - Assessment Report

Adopted

Reference Number: EMA/513755/2023

English (EN) (449.32 KB - PDF)

**First published:** 07/12/2023

[View](/en/documents/variation-report/vimpat-h-c-863-p46-047-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-046 : EPAR - Assessment Report

Adopted

Reference Number: EMA/265194/2023

English (EN) (251.3 KB - PDF)

**First published:** 09/06/2023

[View](/en/documents/variation-report/vimpat-h-c-863-p46-046-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-045 : EPAR - Assessment Report

Adopted

Reference Number: EMA/110067/2023

English (EN) (298.52 KB - PDF)

**First published:** 08/03/2023

[View](/en/documents/variation-report/vimpat-h-c-863-p46-045-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-043 : EPAR - Assessment Report

Adopted

Reference Number: EMA/690309/2022

English (EN) (463.36 KB - PDF)

**First published:** 30/08/2022

[View](/en/documents/variation-report/vimpat-h-c-863-p46-043-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-042 : EPAR - Assessment Report

Adopted

Reference Number: EMA/254431/2022

English (EN) (201.44 KB - PDF)

**First published:** 17/05/2022

[View](/en/documents/variation-report/vimpat-h-c-863-p46-042-epar-assessment-report_en.pdf)

Vimpat-H-C-863-WS-2049G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/99116/2022

English (EN) (6.48 MB - PDF)

**First published:** 25/03/2022

[View](/en/documents/variation-report/vimpat-h-c-863-ws-2049g-epar-assessment-report-variation_en.pdf)

Vimpat-H-C-863-P46-041 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/95791/2022

English (EN) (565.45 KB - PDF)

**First published:** 24/02/2022

[View](/en/documents/variation-report/vimpat-h-c-863-p46-041-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for Vimpat (WS-2049-G)

Adopted

Reference Number: EMA/CHMP/37453/2022

English (EN) (151.59 KB - PDF)

**First published:** 28/01/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vimpat-ws-2049-g_en.pdf)

Vimpat-H-C-863-P46-032 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/590252/2019

English (EN) (218 KB - PDF)

**First published:** 25/01/2022

[View](/en/documents/variation-report/vimpat-h-c-863-p46-032-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-039 : EPAR - Assessment Report

Adopted

Reference Number: EMA/101296/2021

English (EN) (1.29 MB - PDF)

**First published:** 18/02/2021

[View](/en/documents/variation-report/vimpat-h-c-863-p46-039-epar-assessment-report_en.pdf)

Vimpat-H-C-863-WS-1782 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/23665/2021

English (EN) (3.85 MB - PDF)

**First published:** 29/01/2021

[View](/en/documents/variation-report/vimpat-h-c-863-ws-1782-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Vimpat (WS/1782)

Adopted

Reference Number: EMA/CHMP/544470/2020

English (EN) (132.81 KB - PDF)

**First published:** 16/10/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vimpat-ws1782_en.pdf)

Vimpat-H-C-863-P46-037 : EPAR - Assessment Report

Adopted

Reference Number: EMA/261700/2020

English (EN) (764.45 KB - PDF)

**First published:** 16/06/2020

[View](/en/documents/variation-report/vimpat-h-c-863-p46-037-epar-assessment-report_en.pdf)

Vimpat : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/552323/2019

English (EN) (69.14 KB - PDF)

**First published:** 09/10/2019

[View](/en/documents/pip-compliance/vimpat-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Vimpat-H-C-863-P46-0029 : EPAR - Assessment Report

Adopted

Reference Number: EMA/612892/2018

English (EN) (145.24 KB - PDF)

**First published:** 12/10/2018

[View](/en/documents/variation-report/vimpat-h-c-863-p46-0029-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-0028 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/775890/2017

English (EN) (291.84 KB - PDF)

**First published:** 24/11/2017

**Last updated:** 24/11/2017

[View](/en/documents/variation-report/vimpat-h-c-863-p46-0028-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-0027 : EPAR - Assessment Report

Reference Number: EMA/CHMP/643723/2017

English (EN) (256.97 KB - PDF)

**First published:** 08/11/2017

**Last updated:** 08/11/2017

[View](/en/documents/variation-report/vimpat-h-c-863-p46-0027-epar-assessment-report_en.pdf)

Vimpat-H-C-863-II-0065-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/506450/2017

English (EN) (1.91 MB - PDF)

**First published:** 22/09/2017

**Last updated:** 22/09/2017

[View](/en/documents/variation-report/vimpat-h-c-863-ii-0065-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Vimpat (II-65-G)

Reference Number: EMA/CHMP/433563/2017

English (EN) (67.31 KB - PDF)

**First published:** 21/07/2017

**Last updated:** 21/07/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vimpat-ii-65-g_en.pdf)

Vimpat-H-C-863-II-0060-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/132443/2017

English (EN) (1.93 MB - PDF)

**First published:** 05/05/2017

**Last updated:** 05/05/2017

[View](/en/documents/variation-report/vimpat-h-c-863-ii-0060-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Vimpat

Adopted

Reference Number: EMA/CHMP/581734/2016

English (EN) (66.9 KB - PDF)

**First published:** 11/11/2016

**Last updated:** 11/11/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-vimpat_en.pdf)

Vimpat-H-C-863-P46-026 : EPAR - Assessment Report

Adopted

Reference Number: EMA/583608/2015

English (EN) (302.23 KB - PDF)

**First published:** 04/09/2015

**Last updated:** 04/09/2015

[View](/en/documents/variation-report/vimpat-h-c-863-p46-026-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-0025 : EPAR - Assessment Report

Adopted

Reference Number: EMA/381037/2015

English (EN) (1.06 MB - PDF)

**First published:** 09/06/2015

**Last updated:** 09/06/2015

[View](/en/documents/variation-report/vimpat-h-c-863-p46-0025-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-0024 : EPAR - Assessment Report

Adopted

Reference Number: EMA/CHMP/382241/2015

English (EN) (435.63 KB - PDF)

**First published:** 05/06/2015

**Last updated:** 05/06/2015

[View](/en/documents/variation-report/vimpat-h-c-863-p46-0024-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-0023 : EPAR - Assessment Report

Adopted

Reference Number: EMA/414750/2014

English (EN) (98.58 KB - PDF)

**First published:** 01/08/2014

**Last updated:** 01/08/2014

[View](/en/documents/variation-report/vimpat-h-c-863-p46-0023-epar-assessment-report_en.pdf)

Vimpat-H-C-863-P46-0021 : EPAR - Assessment Report

Adopted

Reference Number: EMA/116407/2013

English (EN) (215.65 KB - PDF)

**First published:** 14/03/2013

**Last updated:** 14/03/2013

[View](/en/documents/variation-report/vimpat-h-c-863-p46-0021-epar-assessment-report_en.pdf)

Vimpat-H-C-863-A20-0026 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/923412/2011

English (EN) (88.41 KB - PDF)

**First published:** 22/05/2012

**Last updated:** 22/05/2012

[View](/en/documents/variation-report/vimpat-h-c-863-a20-0026-epar-assessment-report-article-20_en.pdf)

Vimpat-H-C-863-X-0027 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/305791/2012

English (EN) (140.24 KB - PDF)

**First published:** 22/05/2012

**Last updated:** 22/05/2012

[View](/en/documents/variation-report/vimpat-h-c-863-x-0027-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Vimpat : EPAR - Public assessment report

English (EN) (1.49 MB - PDF)

**First published:** 17/09/2008

**Last updated:** 17/09/2008

[View](/en/documents/assessment-report/vimpat-epar-public-assessment-report_en.pdf)

Committee for medicinal products for human use,  summary of positive opinion  for Vimpat

Reference Number: EMEA/CHMP/209605/2008

English (EN) (32.28 KB - PDF)

**First published:** 26/06/2008

**Last updated:** 26/06/2008

[View](/en/documents/smop-initial/committee-medicinal-products-human-use-summary-positive-opinion-vimpat_en.pdf)

#### News on Vimpat

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-january-2022) 28/01/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-october-2020) 16/10/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2017) 21/07/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-november-2016) 11/11/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-december-2011) 16/12/2011

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 September 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-september-2011) 23/09/2011

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Vimpat : EPAR - Product information - tracked changes

English (EN) (697.51 KB - DOCX)

**First published:** 08/05/2025

[View](/en/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-912)

български (BG) (586.97 KB - DOCX)

**First published:**

08/05/2025

[View](/bg/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_bg.docx)

español (ES) (579.05 KB - DOCX)

**First published:**

08/05/2025

[View](/es/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_es.docx)

čeština (CS) (596.09 KB - DOCX)

**First published:**

08/05/2025

[View](/cs/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (488.1 KB - DOCX)

**First published:**

08/05/2025

[View](/da/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (563.12 KB - DOCX)

**First published:**

08/05/2025

[View](/de/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (576.27 KB - DOCX)

**First published:**

08/05/2025

[View](/et/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (592.19 KB - DOCX)

**First published:**

08/05/2025

[View](/el/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_el.docx)

français (FR) (552.5 KB - DOCX)

**First published:**

08/05/2025

[View](/fr/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (483.04 KB - DOCX)

**First published:**

08/05/2025

[View](/hr/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (566.54 KB - DOCX)

**First published:**

08/05/2025

[View](/is/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_is.docx)

italiano (IT) (573.95 KB - DOCX)

**First published:**

08/05/2025

[View](/it/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (580.53 KB - DOCX)

**First published:**

08/05/2025

[View](/lv/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (575.43 KB - DOCX)

**First published:**

08/05/2025

[View](/lt/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (567.86 KB - DOCX)

**First published:**

08/05/2025

[View](/hu/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (553.02 KB - DOCX)

**First published:**

08/05/2025

[View](/mt/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (585.17 KB - DOCX)

**First published:**

08/05/2025

[View](/nl/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (504.37 KB - DOCX)

**First published:**

08/05/2025

[View](/no/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_no.docx)

polski (PL) (574.37 KB - DOCX)

**First published:**

08/05/2025

[View](/pl/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_pl.docx)

português (PT) (528.6 KB - DOCX)

**First published:**

08/05/2025

[View](/pt/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_pt.docx)

română (RO) (564.71 KB - DOCX)

**First published:**

08/05/2025

[View](/ro/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (592.39 KB - DOCX)

**First published:**

08/05/2025

[View](/sk/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (536.81 KB - DOCX)

**First published:**

08/05/2025

[View](/sl/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (533.59 KB - DOCX)

**First published:**

08/05/2025

[View](/fi/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (532.86 KB - DOCX)

**First published:**

08/05/2025

[View](/sv/documents/product-information-tracked-changes/vimpat-epar-product-information-tracked-changes_sv.docx)

- [Clinical data](https://clinicaldata.ema.europa.eu/web/cdp/home?p_p_id=cdpdossierviewportlet_WAR_cdpdossierviewportlet=0=maximized=view=column-3=2=EMEAHC000863II0060G) (variation II/0060)

#### More information on Vimpat

Questions and answers on the review of Vimpat (lacosamide) 15-mg/ml syrup

Reference Number: EMA/CHMP/762478/2011

English (EN) (135.66 KB - PDF)

**First published:** 22/09/2011

**Last updated:** 22/09/2011

[View](/en/documents/medicine-qa/questions-and-answers-review-vimpat-lacosamide-15-mgml-syrup_en.pdf)

Questions and answers on the recall of Vimpat 15-mg/ml syrup (lacosamide)

Reference Number: EMA/CHMP//559522/2011

English (EN) (100.94 KB - PDF)

**First published:** 22/07/2011

**Last updated:** 22/07/2011

[View](/en/documents/medicine-qa/questions-and-answers-recall-vimpat-15-mgml-syrup-lacosamide_en.pdf)

#### More information on Vimpat

- [EMEA-000402-PIP03-17-M08 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000402-pip03-17-m08)
- [EMEA-000402-PIP02-11-M05 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000402-pip02-11-m05)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 21/11/2025

## Share this page

[Back to top](#main-content)